ATLAS-1: Advanced Trial for Longitudinal Assessment in Salma 1
Summary
This study will evaluate the feasibility and clinical utility of developing predictive models of treatment response for patients with depressed mood using multimodal clinical data collected in real-world clinical settings. The study will examine outcomes among patients treated with interventions including esketamine, conventional transcranial magnetic stimulation (TMS), or Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT). Retrospective clinical and research data from existing dat
Eligibility
Inclusion Criteria: * Adults (≥18 years) of any gender identity presenting for care with a depressed mood. * Prescribed treatment with esketamine, conventional TMS, or SAINT as part of standard clinical care. * Able to provide informed consent and comply with all study requirements. Exclusion Crit
Locations
Interested in participating? View the full study details on ClinicalTrials.gov:
View on ClinicalTrials.gov →